



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Incentives for smoking cessation in pregnancy

Citation for published version:

Breunis, L, Bauld, L & Been, JV 2021, 'Incentives for smoking cessation in pregnancy', *British Medical Journal (BMJ)*. <https://doi.org/10.1136/bmj.n2889>

Digital Object Identifier (DOI):

[10.1136/bmj.n2889](https://doi.org/10.1136/bmj.n2889)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

British Medical Journal (BMJ)

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Incentives for smoking cessation in pregnancy: Time for implementation?

Leonieke J Breunis¹, Registrar, PhD student (ORCID 0000-0002-7788-6511); Linda Bauld², Professor (ORCID 0000-0001-7411-4260); Jasper V Been, Consultant Neonatologist, Associate Professor¹⁻⁴ (ORCID 0000-0002-4907-6466)

¹ Department of Obstetrics and Gynaecology, division of Obstetrics and Fetal Medicine, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands

² Usher Institute and SPECTRUM Consortium, The University of Edinburgh, Edinburgh, United Kingdom

³ Department of Paediatrics, division of Neonatology, Erasmus MC Sophia Children's Hospital, University Medical Centre Rotterdam, Rotterdam, The Netherlands

⁴ Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Corresponding author:

Leonieke J. Breunis

l.breunis@erasmusmc.nl

Word count: 681

Smoking during pregnancy is a common modifiable risk factor for adverse child health outcomes.(1) While smoking cessation before and during pregnancy lowers the risk of these adverse outcomes,(2, 3) less than half of women who are daily smokers, successfully quit during pregnancy.(1) This underlines the need for effective interventions to support pregnant women who smoke to quit. Based on evidence from nine randomised controlled trials, a 2019 Cochrane review concluded that provision of incentives effectively promotes sustained smoking cessation during pregnancy.(4) The study of Berlin and colleagues conducted in eighteen French maternity wards further adds to this evidence.(5)

Pregnant women were supported in smoking cessation by provision of six 10-minute face-to-face visits to set a quit date, to provide motivational counselling, support, and skills-training, and to prevent relapse. Women received a €20 voucher at the end of each visit to encourage attendance. Women randomised to the intervention also received incentives for biochemically validated abstinence, increasing in value and amounting to maximally €400. Provision of incentives increased continuous abstinence throughout pregnancy (16.4% versus 7.4%) and point prevalence abstinence (OR 4.61; 95%CI 1.41-15.01), and reduced the risk of poor neonatal outcomes (2.0% versus 8.6%).(5) The relatively large sample size of 460 women and inclusion via several maternity wards spread across the country increase generalisability of the findings. Lack of involvement of the target population during development and implementation of the study and of smoking partners in the intervention are limitations.

The results of this study – combined with those of the Cochrane review and more recent studies – provide compelling evidence that incentives effectively promote smoking cessation during pregnancy.(4, 6-8) Although the effect of incentives on birth outcomes is less clear overall,(9) epidemiological evidence clearly indicates that smoking cessation during pregnancy is associated with reduction of most adverse perinatal health risks.(2) As such, it is reasonable to assume that cessation will translate into perinatal and child health benefits at the population level. Given the clear signal that incentives support pregnant women to quit smoking, how do we take this forward?

Ongoing and future studies can help address some of the remaining questions: what is the optimal incentive scheme (i.e. timing, frequency, value, duration, and type of incentive)? Who should deliver it and how? Could personalised incentives be more effective than a one-size-fits-all approach? Would involvement of a significant other (e.g. the pregnant woman's partner) in the intervention increase effectiveness? Also, given that over 40% of women who successfully quit during pregnancy relapse within six months postpartum, could extension of the intervention to include the postpartum period sustain cessation? This is important as maintaining a smoke-free home will enable children to grow up free from the health hazards associated with tobacco smoke exposure. Evidence from several trials currently underway to address some of these issues will help optimise strategies to support implementation of incentive provision in daily practice.(10-12)

Considering current evidence supporting the effectiveness of incentives for smoking cessation during pregnancy, we argue that implementation should be pursued in parallel with ongoing and future research. Several studies have indicated that incentives are highly cost-effective,(7, 13) and ongoing work will provide more detailed information in the near future.(5, 11) Incentives seem most effective when provided as an adjunct to psychosocial counselling, and as such may be integrated into existing cessation support services.(14) Successful examples are available,(6) and the Royal College of

Physicians and Royal College of Midwives have already argued that financial incentives should routinely be offered to promote smoking cessation during pregnancy.(15, 16) This is supported in forthcoming NICE guidance in the UK.(17) Integration in national best-practice guidelines and determining responsibility for implementation, service provision, and cost coverage will be important in shaping national and local strategies. Appropriate consideration of ethical aspects is also essential.(18) Involvement of the pregnant women and their families will help ensure that local implementation will be culturally appropriate.(19)

This study adds to growing evidence that the time is right to start including incentive provision as part of standard practice to support smoking cessation during pregnancy. Doing so will also play an important role in reducing health inequalities at their earliest origin.

STATEMENTS

The BMJ has judged that there are no disqualifying financial ties to commercial companies.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

REFERENCES

1. Lange S, Probst C, Rehm J, Popova S. National, regional, and global prevalence of smoking during pregnancy in the general population: a systematic review and meta-analysis. *The Lancet Global Health*. 2018;6(7):e769-e76.
2. Räisänen S, Sankilampi U, Gissler M, Kramer MR, Hakulinen-Viitanen T, Saari J, et al. Smoking cessation in the first trimester reduces most obstetric risks, but not the risks of major congenital anomalies and admission to neonatal care: a population-based cohort study of 1 164 953 singleton pregnancies in Finland. *Journal of Epidemiology and Community Health*. 2014;68(2):159-64.
3. Liu B, Xu G, Sun Y, Qiu X, Ryckman KK, Yu Y, et al. Maternal cigarette smoking before and during pregnancy and the risk of preterm birth: A dose-response analysis of 25 million mother-infant pairs. *PLoS Med*. 2020;17(8):e1003158.
4. Notley C, Gentry S, Livingstone-Banks J, Bauld L, Perera R, Hartmann-Boyce J. Incentives for smoking cessation. *Cochrane Database of Systematic Reviews*. 2019(7).
5. Berlin I, Berlin N, Malecot M, Breton M, Jusot F, Goldzahl L. Financial incentives for smoking cessation in pregnancy. A randomised, controlled, multicenter, clinical trial (the FISCP trial). *BMJ*. 2021.
6. Petersen AB, Ogunrinu T, Wallace S, Yun J, Belliard JC, Singh PN. Implementation and Outcomes of a Maternal Smoking Cessation Program for a Multi-ethnic Cohort in California, USA, 2012–2019. *Journal of Community Health*. 2021.

7. Polinski KJ, Wolfe R, Peterson A, Juhl A, Perraiillon MC, Levinson AH, et al. Impact of an incentive-based prenatal smoking cessation program for low-income women in Colorado. *Public Health Nurs.* 2020;37(1):39-49.
8. Olson AL, Boardman MB, Johnson DJ. Smoke-Free Moms: Financial Rewards for Smoking Cessation by Low-Income Rural Pregnant Women. *Am J Prev Med.* 2019;56(6):852-9.
9. McConnachie A, Haig C, Sinclair L, Bauld L, Tappin DM. Birth weight differences between those offered financial voucher incentives for verified smoking cessation and control participants enrolled in the Cessation in Pregnancy Incentives Trial (CPIT), employing an intuitive approach and a Complier Average Causal Effects (CACE) analysis. *Trials.* 2017;18(1):337.
10. Ussher M, Best C, Lewis S, McKell J, Coleman T, Cooper S, et al. Financial Incentives for Preventing Postpartum return to Smoking (FIPPS): study protocol for a three-arm randomised controlled trial. *Trials.* 2021;22(1):512.
11. Sinclair L, McFadden M, Tilbrook H, Mitchell A, Keding A, Watson J, et al. The smoking cessation in pregnancy incentives trial (CPIT): study protocol for a phase III randomised controlled trial. *Trials.* 2020;21(1):183.
12. Boderie NW, van Kippersluis JL, Ó Ceallaigh DT, Radó MK, Burdorf A, van Lenthe FJ, et al. PERSONalised Incentives for Supporting Tobacco cessation (PERSIST) among healthcare employees: a randomised controlled trial protocol. *BMJ Open.* 2020;10(9):e037799.
13. Boyd KA, Briggs AH, Bauld L, Sinclair L, Tappin D. Are financial incentives cost-effective to support smoking cessation during pregnancy? *Addiction.* 2016;111(2):360-70.
14. Smoking in pregnancy challenge group. Evidence into practice: Supporting smokefree pregnancies through incentive schemes. 2019.
15. The Royal College of Midwives. Position Statement: support to quit smoking in pregnancy. 2019.
16. Royal College of Physicians. Smoking and Health 2021. A coming of age for tobacco control? 2021.
17. National Institute for Health and Care Excellence (NICE). NICE and PHE publish comprehensive draft guideline to tackle the health burden of smoking. 2021.
18. Breunis LJ, Been JV, de Jong-Potjer L, Steegers EA, de Beaufort ID, de Kroon M, et al. Incentives for Smoking Cessation During Pregnancy: An Ethical Framework. *Nicotine Tob Res.* 2020;22(9):1553-9.
19. Breunis LJ, de Kroon MLA, Laureij LT, de Jong-Potjer L, Steegers EAP, Been JV. Smoke and Alcohol Free with EHealth and Rewards (SAFER) pregnancy study: a before-after study protocol. *NPJ Prim Care Respir Med.* 2020;30(1):51.